tgoop.com/educationalcommittee4/8225
Last Update:
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
The U.S. Food and Drug Administration approved Zurnai, the first (nalmefene hydrochloride) auto-injector for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. The agency approved the first nasal spray formulation of nalmefene in May 2023.
من المعروف فيما يتعلق بمضادات opioide naloxone and naltrexone.
الآن منظمة FDA تصرح بأستخدام دواء. Nalmafene كمضاد لل Opioids ومتوفر auto injector تحقن تحت الجلد أو في العضلات بجرعة 1.5mg.
Nalmefene is an opioid receptor antagonist which is used to treat acute opioid overdose. If nalmefene is administered quickly, it can reverse the effects of opioid overdose, including respiratory depression, sedation and low blood pressure (hypotension). The newly approved product delivers 1.5 milligrams (mg) of nalmefene under the skin (subcutaneous) or into muscle (intramuscular). Zurnai is a and is available only by prescription.
BY اللجنة العلمية# الدفعة الرابعة ❈صيدلة❈
Share with your friend now:
tgoop.com/educationalcommittee4/8225